Eoin McDonnell

Eoin McDonnell is the co-founder and CEO of Tavros Therapeutics since October 2019. Prior experience includes roles as a consultant and senior scientist at Element Genomics from January 2018 to January 2020, where work focused on CRISPR/Cas9-based tools, contributing to the company's acquisition by UCB Pharma. Eoin served as a postdoctoral fellow at Pfizer from December 2016 to January 2018, researching the effectiveness and resistance mechanisms of the CDK4/6 inhibitor palbociclib in ER+ breast cancer. Eoin completed a PhD in Molecular Cancer Biology at Duke University, where research emphasized cellular metabolism in cancer, and held laboratory technician and assistant positions in various projects related to cancer treatment and gene function at Duke University and Integrated Oncology Solutions. Eoin holds a Bachelor of Science in Biology from Virginia Tech, earned in 2009.